Sun Pharma Strengthens India’s Pharma Backbone with Major Assam Investment

A ₹500 crore manufacturing plant promises new medicines, new jobs, and sustainable growth in the Northeast

Sun Pharmaceutical, India’s largest drug maker, is set to make a significant mark in the Northeast with a ₹500 crore investment to establish a new pharmaceutical manufacturing facility in Assam. The project is expected to create more than 500 direct jobs, offering a major boost to both healthcare manufacturing and local employment.

Senior leaders from Sun Pharma recently met with Assam Chief Secretary Ravi Kota in Guwahati to discuss the roadmap for the proposed plant. The facility will focus on drug formulation manufacturing, aimed primarily at serving the Indian market. According to officials, the investment will be rolled out in two phases, allowing the project to scale steadily while ensuring operational readiness.

Sharing details of the discussion, Ravi Kota said the meeting reviewed “the company’s proposal for setting up pharmaceutical manufacturing facilities in Assam,” highlighting key requirements such as land, power and water availability, transport connectivity, and access to skilled talent.

Beyond production capacity, the company has placed a strong emphasis on sustainable pharmaceutical manufacturing. Plans include efficient use of water, greater reliance on renewable energy, and responsible waste management, aligning with India’s environmental standards and global best practices in the pharma sector.

The Assam government sees the project as part of its broader effort to attract high-value investments that support inclusive development and long-term economic growth. With its global footprint spanning more than 100 countries and over 40 manufacturing facilities worldwide, Sun Pharma’s decision to expand in Assam signals growing confidence in the state as an emerging pharmaceutical hub.